Project Grant HT9425261E036
- Federal Project Grant Award Summary New York University School of Medicine received a $1.67M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Identifying Pathways That Prevent the Emergence of Drug-Tolerant Persisters." The three-year award, which commenced September 30, 2026 and concludes September 29, 2029, supports investigator-initiated biomedical research aligned with DHA's...
- Federal Project Grant Award Summary New York University received an $818,929 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, with an ultimate completion date of September 29, 2029. The award funds the implementation of a formal postvention program designed to support military mental health clinicians. Postvention services typically focus on intervention and support following critical incidents,...
- Federal Grant Award Summary New York University School of Medicine received a $750,962 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on June 15, 2026, with a completion date of June 14, 2029. The project, titled "Neoadjuvant Checkpoint and IL-6 Blockade: Mechanisms of Benefit and Toxicity," supports biomedical research investigating immunotherapy approaches and their clinical outcomes. This...
- Federal Project Grant Award Summary New York University School of Medicine received a $1.35M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded June 15, 2026, with completion targeted for June 14, 2029. The project, titled "Neoadjuvant Checkpoint and IL-6 Blockade: Mechanisms of Benefit and Toxicity," supports biomedical research investigating immunotherapy approaches for cancer treatment. The research...
- Federal Grant Award Summary New York University School of Medicine received a $2.01M Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2025, through June 30, 2028. The award supports research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation," conducted at NYU's location in New York, New York. This research investigates the...
- Federal Grant Award Summary New York University School of Medicine has received a $680,757 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation." The three-year award, effective July 1, 2025 through June 30, 2028, supports biomedical research investigating the mechanisms by which particulate matter...
- Federal Project Grant Award Summary New York University received a $791,063 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded on September 30, 2025, with an ultimate completion date of September 29, 2029. The award funds the implementation of a formal postvention program designed to serve military mental health clinicians. Postvention—intervention following a suicide or suicide attempt—represents a critical gap in...
- Federal Grant Award Summary New York University School of Medicine has received a $2.54 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025 through July 31, 2028. The award supports research and development activities focused on advancing a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS) treatment through investigation of the RAGE/DIAPH1 axis. As a premier academic medical...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded $352,000 under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute for Cancer Research for the project period September 1, 2025, through August 31, 2027. The award supports research focused on augmenting the in vivo efficacy of a novel lanosterol synthase inhibitor in glioblastoma treatment. This research aligns with the DHA's mission to transform healthcare for service...
- Federal Project Grant Award Summary Weill Medical College of Cornell University received a $1,017,003 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded June 1, 2026, with a completion date of May 31, 2029. The award funds investigator-initiated biomedical research focused on pharmacological targeting of UBR5 (Ubiquitin Ligase RBR Family Member 5) for breast cancer immunotherapy. This three-year project represents...
New York University School of Medicine received a $833,334 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective September 30, 2026, with a completion date of September 29, 2029. The award supports a three-year research initiative titled "Identifying Pathways that Prevent the Emergence of Drug-Tolerant Persisters," which investigates mechanisms to prevent the development of drug-resistant cellular populations—a critical challenge in treating infectious diseases and cancers affecting Service Members and the broader population. The funded research represents a hypothesis-driven, translational investigation consistent with NYU School of Medicine's biomedical research portfolio and the DHA's mission to advance medical solutions for military health concerns. The project aligns with the Military Medical Research and Development program's focus on basic and applied biomedical research addressing Service Member health outcomes. As a major academic medical center with substantial federal research engagement, NYU School of Medicine will conduct the investigation at its New York, New York facility, leveraging institutional expertise in infectious disease and cancer biology research to generate findings applicable to both military and civilian populations.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $833.3k | 4/2/26 |